Nephrology

Gout

Questions discussed in this category

If a patient who has tolerated allopurinol for a prolonged period of time is subsequently found to be positive for the HLA-B*58:01 gene, how would you manage urate-lowering therapy thereafter?

1 Answer available

How do you approach urate-lowering therapy in patients with advanced chronic kidney disease?

What doses of allopurinol do you use, and how frequently do you titrate the dose?

1 Answer available

How do you use colchicine for gout in patients with chronic kidney disease or end-stage renal disease on hemodialysis?

2 Answers available

Do you eventually stop urate-lowering therapy in gout patients with CKD who start hemodialysis?

1 Answer available

Papers discussed in this category

Arthritis care & research, 2012-10

2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.

Proceedings of the National Academy of Sciences of the United States of America, 2005 Mar 02

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.

Related Topics in Nephrology